NF Trinity Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

NF Trinity Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$11.2M	Buy	82,500 +20,000	+32%	+$2.49M	1.78%	15
2018 Q4	$6.08M	Hold	62,500	–	–	0.99%	27
2018 Q3	$8.69M	Buy	62,500 +16,500	+36%	+$2.07M	1.15%	23
2018 Q2	$5.71M	Hold	46,000	–	–	0.78%	32
2018 Q1	$5.13M	Hold	46,000	–	–	0.71%	34
2017 Q4	$5.5M	Hold	46,000	–	–	0.72%	31
2017 Q3	$6.45M	Hold	46,000	–	–	0.92%	29
2017 Q2	$5.6M	Hold	46,000	–	–	0.79%	29
2017 Q1	$5.58M	Hold	46,000	–	–	0.75%	28
2016 Q4	$5.63M	Hold	46,000	–	–	0.79%	29
2016 Q3	$5.64M	Buy	+46,000	New	+$5.92M	0.63%	32

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

NF Trinity Capital's ALXN Position: Q1 2019 in Review

NF Trinity Capital increased its Alexion Pharmaceuticals (ALXN) stake by 32% in Q1 2019, buying an estimated $2.49M and bringing the position to 82,500 shares worth $11.2M. The position accounts for 1.78% of the portfolio, ranked #15.

NF Trinity Capital first reported a position in ALXN in Q3 2016 and has held it in 11 quarters since. 611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

NF Trinity Capital held 82,500 shares of Alexion Pharmaceuticals worth $11.2M as of Q1 2019.
NF Trinity Capital bought 20,000 Alexion Pharmaceuticals shares in Q1 2019, an estimated $2.49M.
Alexion Pharmaceuticals made up 1.78% of NF Trinity Capital's portfolio in Q1 2019, its #15 holding.
NF Trinity Capital first reported a position in Alexion Pharmaceuticals in Q3 2016 and has held it in 11 quarters since.
611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on NF Trinity Capital's 13F filing for Q1 2019, filed 10 May 2019.